ScholarLens Back to search
2019•European Urology SupplementsRequires access

Switch from prednisone to dexamethasone in patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in a multicenter study

Ines RIVERO BELENCHON, Carmen Muñoz-Calahorro, I. Osmán García, Pastora Beardo Villar, C.B. Congregado Ruíz, B. San José Ruíz Jiménez, J. Campá Bortoló, Roberto Llarena Ibarguren, Javier Extramiana Cameno, R.A. Medina López, Juan Pinto Sánchez

Open publisher page 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Abiraterone acetate, Medicine, Prednisone, Prostate cancer, Dexamethasone, Oncology, Internal medicine, Abiraterone

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Switch from prednisone to dexamethasone in patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in a multicenter study — Research Paper | ScholarLens